Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis
September 09, 2024 07:00 ET
|
Cartesian Therapeutics, Inc.
GAITHERSBURG, Md., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...
Cartesian Therapeutics Announces New Employment Inducement Grant
September 06, 2024 07:05 ET
|
Cartesian Therapeutics, Inc.
GAITHERSBURG, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the...
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15
September 03, 2024 07:00 ET
|
Cartesian Therapeutics, Inc.
Descartes-15 observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing in preclinical studies GAITHERSBURG, Md., Sept. ...
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
August 26, 2024 07:00 ET
|
Cartesian Therapeutics, Inc.
GAITHERSBURG, Md., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...
Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024 07:00 ET
|
Cartesian Therapeutics, Inc.
Presented positive topline results from Phase 2b trial of Descartes-08 in patients with myasthenia gravis; End-of-Phase 2 meeting with FDA expected by year-end Dosed first SLE patient in Phase 2...
Cartesian Therapeutics Announces New Employment Inducement Grants
August 07, 2024 16:05 ET
|
Cartesian Therapeutics, Inc.
GAITHERSBURG, Md., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the...
Cartesian Therapeutics Announces New Employment Inducement Grants
July 08, 2024 16:05 ET
|
Cartesian Therapeutics, Inc.
GAITHERSBURG, Md., July 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the...
Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik
July 02, 2024 16:05 ET
|
Cartesian Therapeutics, Inc.
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
July 02, 2024 06:31 ET
|
Cartesian Therapeutics, Inc.
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
July 02, 2024 06:31 ET
|
Cartesian Therapeutics, Inc.
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune...